Genmab A/S
GMAB28.660USD
-0.180-0.62%
收盤 11/07, 16:00（美東）報價延遲15分鐘
17.65B總市值
11.91本益比TTM
關於 Genmab A/S 公司
Genmab A/S 是一家總部位於丹麥的國際生物技術公司。該公司專門從事用於治療癌症的抗體療法的研發。該公司是以下獲批抗體的創造者：用於治療某些多發性骨髓瘤適應症的 DARZALEX（daratumumab）、用於治療復發型多發性硬化症成人患者的 Kesimpta、用於治療甲狀腺眼病的 TEPEZZA（teprotumumab）和用於治療某些多發性骨髓瘤適應症成人患者的 FASPRO。Genmab 創造的首個獲批療法 Arzerra 獲批用於治療某些慢性淋巴細胞白血病適應症，在日本有售，也可通過同情用藥或腫瘤學獲取計劃在其他地區有售。Genmab 開發了廣泛的臨牀和臨牀前產品線，擁有四種抗體技術，即 DuoBody 雙特異性平臺、HexaBody 平臺、DuoHexaBody 平臺和 HexElect 平臺。
Genmab A/S簡介
公司代碼GMAB
公司名稱Genmab A/S
上市日期Oct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
員工數量2682
證券類型Ordinary Share
年結日Oct 01
公司地址Carl Jacobsens Vej 30
城市VALBY
上市交易所OMX Nordic Exchange Copenhagen A/S
國家Denmark
郵編2500
電話4570202728
網址https://www.genmab.com/
公司代碼GMAB
上市日期Oct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
Genmab A/S公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
股東統計
更新時間: 11月8日 週六
更新時間: 11月8日 週六
持股股東
股東類型
持股股東
持股股東
佔比
AllianceBernstein L.P.
1.73%
Orbis Investment Management Ltd.
1.29%
Citadel Advisors LLC
0.58%
Arrowstreet Capital, Limited Partnership
0.56%
Two Sigma Investments, LP
0.56%
其他
95.28%
持股股東
持股股東
佔比
AllianceBernstein L.P.
1.73%
Orbis Investment Management Ltd.
1.29%
Citadel Advisors LLC
0.58%
Arrowstreet Capital, Limited Partnership
0.56%
Two Sigma Investments, LP
0.56%
其他
95.28%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
4.32%
Investment Advisor
3.18%
Hedge Fund
2.35%
Research Firm
0.64%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.01%
其他
89.45%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
AllianceBernstein L.P.
10.66M
1.73%
-4.06M
-27.59%
Jun 30, 2025
Orbis Investment Management Ltd.
7.92M
1.29%
+2.21M
+38.69%
Jun 30, 2025
Citadel Advisors LLC
3.57M
0.58%
-857.47K
-19.37%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
3.45M
0.56%
+2.08M
+152.25%
Jun 30, 2025
Two Sigma Investments, LP
3.44M
0.56%
-433.92K
-11.20%
Jun 30, 2025
Harding Loevner LP
2.92M
0.48%
+42.61K
+1.48%
Jun 30, 2025
Renaissance Technologies LLC
2.77M
0.45%
+504.40K
+22.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.50M
0.41%
-443.29K
-15.04%
Jun 30, 2025
Marshall Wace LLP
1.91M
0.31%
-274.23K
-12.57%
Jun 30, 2025
First Trust Advisors L.P.
1.77M
0.29%
+60.50K
+3.54%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Tema Oncology ETF
5.08%
First Trust NYSE Arca Biotechnology Index Fund
4.45%
WisdomTree BioRevolution Fund
1.33%
iShares Biotechnology ETF
1.32%
AB Disruptors ETF
0.92%
First Trust NASDAQ BuyWrite Income ETF
0.29%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
ActivePassive International Equity ETF
0.13%
Avantis International Equity ETF
0.1%
查看更多
Tema Oncology ETF
佔比5.08%
First Trust NYSE Arca Biotechnology Index Fund
佔比4.45%
WisdomTree BioRevolution Fund
佔比1.33%
iShares Biotechnology ETF
佔比1.32%
AB Disruptors ETF
佔比0.92%
First Trust NASDAQ BuyWrite Income ETF
佔比0.29%
ProShares Ultra Nasdaq Biotechnology
佔比0.13%
Invesco Nasdaq Biotechnology ETF
佔比0.13%
ActivePassive International Equity ETF
佔比0.13%
Avantis International Equity ETF
佔比0.1%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
